Innovent Biologics, Inc. annonce l'approbation par l'Administration nationale des produits médicaux du nouvel inhibiteur non covalent (réversible) de la tyrosine kinase de ...

Innovent Biologics, Inc. a annoncé que l'inhibiteur non covalent de la tyrosine kinase de Bruton , Jaypirca®? , a reçu l'approbation de l'Administration nationale des produits médicaux en ...
Business Wire

Avistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference on Molecular Targets and ...

BEIJING, China--(BUSINESS WIRE)--Avistone Biotechnology Co., Ltd (“Avistone” or “the Company”), a clinical-stage biotechnology company focused on precision oncology therapeutics, today announced ...
ascopubs.org

Osimertinib Versus First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Metastatic EGFR-Mutant Non–Small Cell Lung Cancer: A Target Trial ...

Although clinical trials support osimertinib's efficacy over standard epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in metastatic EGFR-mutant non–small cell lung cancer ...
C&EN

Kinase inhibitors can be targeted protein degraders too

An illustration shows the structure of an inhibitor bound to the active site of membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase. An inhibitor bound to the active site of ...